

RECEIVED  
CENTRAL FAX CENTER

APR 19 2005

*Lilly*

Fax

Eli Lilly and Company  
Lilly Corporate Centre  
Indianapolis, Indiana 46285  
U.S.A.

Date: 19 April 2005

To: B. Celsa  
Company: USPTO, Technology Center 1600  
Fax: 1-703-872-9306

From: Paula Davis  
Phone: 317-433-3422  
Fax: 317-276-5172  
Total Pages: 26

**Privileged and Confidential Communication**

Re: Application No.: 09/748,739  
Applicant's File Reference: X-16699

If there are any transmittal problems, please contact Jan Fowler at 317-655-1715.  
This facsimile message is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify us immediately by telephone (collect).

Answers That Matter.

APR 19 2005

CERTIFICATION OF FACSIMILE TRANSMISSION	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
<u>JANET Fowler</u> Type or print name of person signing certification	
<u>Janet Fowler</u> Signature	<u>4/19/2005</u> Date

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant: Oksana Lockridge & Jeffry Watkins      Group Art Unit: 1639  
Serial No.: 09/748,739  
Filed: December 26, 2000      Examiner: B. Celsa  
For: Butyrylcholinesterase Variants and  
Methods of Use  
Docket No.: X16699

**REPLY UNDER 37 C.F.R. 1.111 & AMENDMENT UNDER 37 C.F.R. 1.121**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**Introductory Comments**

In response to the Office Action dated January 19, 2005, Paper No. 20050111, the Applicants offer the following comments and amendments and respectfully request reconsideration of the present application.

Although the Applicants believe that no additional fees are due because this reply is being submitted within three months of the Office Action, Applicants authorize the Office to charge any necessary fees to Deposit Account No. 05-0840 in the name of Eli Lilly and Company.